← All trials
NCT05179239
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 26, 2022
- Primary completion
- Mar 30, 2024
- Completion date
- May 31, 2025
- First posted
- Jan 5, 2022
- Last posted
- Mar 29, 2022
- Enrollment
- 572
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.